| Medical and Health Sciences | 2021-2025 | 169 | US 64 | 99.97 |
| Pulmonary and Respiratory Medicine | Lifetime | 518 | US 274 | 99.28 |
| Oncology | Lifetime | 807 | US 443 | 98.29 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 19 | US 7 | 99.91 |
| Oncology | 2021-2025 | 36 | US 12 | 99.81 |
| Surgery | 2021-2025 | 290 | US 120 | 98.13 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 298 | US 103 | 94.25 |
| Cancer Research | 2021-2025 | 159 | US 55 | 91.74 |
| Prostate Cancer Treatment and Research | Lifetime | 287 | US 167 | 99.11 |
| Renal cell carcinoma treatment | Lifetime | 231 | US 138 | 98.82 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 269 | US 122 | 98.26 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 561 | US 286 | 98.76 |
| PARP inhibition in cancer therapy | Lifetime | 122 | US 61 | 98.20 |
| Cancer, Lipids, and Metabolism | Lifetime | 806 | US 377 | 97.21 |
| Renal and related cancers | Lifetime | 666 | US 330 | 97.07 |
| Bladder and Urothelial Cancer Treatments | Lifetime | 748 | US 327 | 97.28 |
| Economic and Financial Impacts of Cancer | Lifetime | 655 | US 416 | 93.91 |
| Urinary and Genital Oncology Studies | Lifetime | 825 | US 356 | 95.36 |
| Multiple and Secondary Primary Cancers | Lifetime | 970 | US 415 | 91.53 |
| Prostate Cancer Treatment and Research | 2021-2025 | 7 | US 2 | 99.91 |
| PARP inhibition in cancer therapy | 2021-2025 | 6 | US 2 | 99.73 |
| Renal cell carcinoma treatment | 2021-2025 | 14 | US 7 | 99.56 |
| DNA Repair Mechanisms | 2021-2025 | 9 | US 5 | 98.38 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 18 | US 8 | 99.61 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 95 | US 35 | 99.63 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 52 | US 21 | 98.51 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 73 | US 31 | 98.87 |
| Cancer Genomics and Diagnostics | 2021-2025 | 205 | US 99 | 98.38 |
| Renal and related cancers | 2021-2025 | 55 | US 28 | 97.85 |
| Urinary and Genital Oncology Studies | 2021-2025 | 59 | US 26 | 98.30 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 106 | US 63 | 96.15 |
| Prostate Cancer Diagnosis and Treatment | 2021-2025 | 455 | US 142 | 95.22 |
| Advanced Breast Cancer Therapies | 2021-2025 | 282 | US 103 | 95.00 |
| Hormonal and reproductive studies | 2021-2025 | 160 | US 37 | 92.88 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 128 | US 57 | 89.30 |
| Cancer Diagnosis and Treatment | 2021-2025 | 317 | US 77 | 85.58 |
| Cancer Treatment and Pharmacology | 2021-2025 | 625 | US 220 | 88.62 |
| Bone health and treatments | 2021-2025 | 418 | US 65 | 83.23 |
| Cell death mechanisms and regulation | 2021-2025 | 431 | US 85 | 60.82 |
